Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100T4L7
Period2023-01-01 → 2023-12-31
Filed2024-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amended by S100USPT (2024-11-15).

Key figures · 77
MetricValuePeriodScopeSource row
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥481m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥448m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax−¥1.2bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.5bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥3.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.6bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥173,0002023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥35m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥4m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥26m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥667m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥271m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.9bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.062020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-44.612019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥21.66at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥36.7at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥77.99at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥78.1at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio92.6%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued39,505,200at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued33,283,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees51at 2023-12-31StandaloneNumber of employees
Employees49at 2022-12-31StandaloneNumber of employees
Employees49at 2021-12-31dStandaloneNumber of employees
Employees42at 2020-12-31dStandaloneNumber of employees
Employees38at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 19
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2023-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥552m
Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-12-31−¥1.1bn
Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-12-31¥682m
Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-12-31¥682m
Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-12-31¥399m
—segment totalemployeesat 2023-12-3140 pure
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-12-31¥682m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-12-31¥682m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-12-31−¥653m
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥472m
Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.1bn
Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-12-31¥349m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-12-31−¥787m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 835
ItemContextValueUnit
Short term loans payableCurrentYearInstant_NonConsolidatedMember291000000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember70800000JPY
Accounts payable otherCurrentYearInstant_NonConsolidatedMember116952000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember26558000JPY
Accrued expensesCurrentYearInstant_NonConsolidatedMember25587000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember23943000JPY
Income taxes payableCurrentYearInstant_NonConsolidatedMember23952000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember22100000JPY
Advances receivedCurrentYearInstant_NonConsolidatedMember31200000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember4835000JPY
Deposits receivedCurrentYearInstant_NonConsolidatedMember5880000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember6351000JPY
Provision for bonusesCurrentYearInstant_NonConsolidatedMember6730000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember370455000JPY
Current liabilitiesCurrentYearInstant_NonConsolidatedMember539038000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember54268000JPY
Asset retirement obligations nclCurrentYearInstant_NonConsolidatedMember54692000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember54268000JPY
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember54692000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember424724000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember593731000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember2097017000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember2388422000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember3696798000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember3988202000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3696798000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember3988202000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember-4016331000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember-5236350000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-4016331000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember-5236350000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentYearInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1777192000JPY
Shareholders equityCurrentYearInstant_NonConsolidatedMember1139981000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember13554000JPY
Subscription rights to sharesCurrentYearInstant_NonConsolidatedMember17741000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1790746000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember1157723000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2215470000JPY
Liabilities and net assetsCurrentYearInstant_NonConsolidatedMember1751454000JPY
Net salesPrior1YearDuration_NonConsolidatedMember630815000JPY
Net salesCurrentYearDuration_NonConsolidatedMember682464000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember281957000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember283869000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember348858000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember398595000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1135613000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1051904000JPY
Other sgaPrior1YearDuration_NonConsolidatedMember471899000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass